- Home
- SOWG vs TCRX Comparison
SOWG vs TCRX Comparison
Compare SOWG & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOWG | TCRX |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.9M | 49.4M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SOWG | TCRX |
|---|---|---|
| Price | $3.07 | $0.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 7.4K | ★ 470.5K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $0.10 | $0.72 |
| 52 Week High | $4.45 | $2.57 |
Technical Indicators
Market Signals| Indicator | SOWG | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.28 | 44.78 |
| Support Level | $2.45 | $0.73 |
| Resistance Level | $3.50 | $0.80 |
| Average True Range (ATR) | 0.25 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 52.13 | 50.25 |
Price Performance
Historical ComparisonAbout SOWG Sow Good Inc.
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.